In Vivo Infographics
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. In Vivo's sister publication Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023.
10 Years On, Chinese Biopharma Firms Making US Inroads: A Snapshot
From 2013 to November 2022, Chinese pharma companies as a single sponsor started a total of 35 international Phase III clinical studies for innovative drugs in the US, indicating a continuing push by the biopharma sector in the country to leverage increasing innovation to access this huge and lucrative market. Led by BeiGene, 20 firms have placed their bets on such studies and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Snapshot: October Highlights
A selection of articles you might have missed from October 2022, including discussions on inclusion in the pharmaceutical industry, cancer vaccine development and where it is taking place, and the importance of digital tools beyond care.
Big In Japan: Assessing Seven Years Of Sakigake
Japan’s fast-track approval system for innovative drug candidates has marked its seventh year since launch, during which it has accepted 27 candidates with 13 of these moving to approval. But in recent years the system has faced a decreasing number of admitted candidates, this original infographic analysis shows.
Sweden: On The Cutting Edge Of Life Sciences
Sweden is a European leader in the life sciences and now has its sights set on becoming a global force in digital and e-health. A rich academic tradition, strong manufacturing infrastructure and health care as a pillar of its unique Mixed Economy make Sweden an attractive home for pharma, biotech and medtech companies and a target for investors.
Early Days For The Metaverse In The Life Sciences, But Experimentation Is Happening
Hype around the metaverse has made it a sexy topic, but a recent Accenture report grounds the concept in a sober, yet still exciting, reality. The consulting firm looked at how the metaverse is being applied in the life sciences sector and concluded that while it is early days and the concept remains nebulous, executives would be remiss if they ignored the growing possibilities the metaverse has to offer.
Cancer Vaccines: Active Companies and Competitor Landscape
In Vivo takes a look at the global cancer vaccine development landscape, which companies are developing vaccines, for which cancers, and in which geographies?
Snapshot: September Highlights
A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.
Seven Potential Blockbuster Approvals To Look Out For In 2023
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?
INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. In Vivo's sister publication Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022.
Snapshot: August Highlights
A selection of articles you might have missed from August 2022, including a discussion on fake medicines and what's needed to tackle their existence, the die down of SPAC deals and how device-activated drugs may unlock new therapeutic avenues.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.